Free tool
Drug Trial Radar: Gastroenterology and liver
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
13
Active, not recruiting, industry sponsors, Gastroenterology and liver, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed310
13 trials
Showing 1 to 13, recently updated first.
- A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This ConditionPivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05519475 · 120 participants (planned) · Start Feb 9, 2023 · Primary completion Apr 27, 2028
Drug: ALN-HSD; Placebo · For: Metabolic Dysfunction-Associated SteatoHepatitis (MASH)
Sites: Flagstaff, Arizona; Peoria, Arizona; Tucson, Arizona · 71 sites in all
- A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)Pivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06836609 · 118 participants · Start Apr 28, 2025 · Primary completion Aug 17, 2027
Drug: ALN-CIDEB; Placebo · For: Metabolic Dysfunction-Associated Steatotic Liver Disease; Metabolic Dysfunction-Associated Steatohepatitis
Sites: Chandler, Arizona; Tucson, Arizona; London, United Kingdom · 4 sites in all
- A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and OverweightPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06151964 · 166 participants · Start Sep 29, 2023 · Primary completion Jan 29, 2027
Drug: AZD9550; placebo and 1 more · For: Overweight and Obesity
Sites: Graz, Austria; Vienna, Austria; Surrey, Canada · 15 sites in all
- A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 WeeksActive, not recruiting
Phathom Pharmaceuticals, Inc.Industry
NCT06851559 · 95 participants · Start Oct 30, 2025 · Primary completion Sep 11, 2026
Drug: Vonoprazan; Placebo · For: Eosinophilic Esophagitis
Sites: Little Rock, Arkansas; Chula Vista, California; Los Angeles, California · 41 sites in all
- A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary CholangitisPivotal-lookingActive, not recruiting
Mirum Pharmaceuticals, Inc.Industry
NCT05050136 · 333 participants · Start Sep 22, 2021 · Primary completion Jan 2027
Drug: Volixibat; Placebo · For: Primary Biliary Cholangitis; PBC
Sites: Coronado, California; Los Angeles, California; Sacramento, California · 130 sites in all
- Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD SubjectsPivotal-lookingActive, not recruiting
Zhejiang Doer Biologics Co., Ltd.Industry
NCT07024212 · 110 participants (planned) · Start Apr 22, 2025 · Primary completion Jun 18, 2026
Drug: DR10624 Injection; Placebo · For: MASLD
Sites: Hangzhou, China; Changchun, China; Nanjing, China · 4 sites in all
- A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May HaveActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05831176 · 22 participants · Start May 3, 2023 · Primary completion Feb 23, 2026
Drug: Dupilumab · For: Eosinophilic Gastritis (EoG); Eosinophilic Duodenitis (EoD); Eosinophilic Gastrointestinal Disease (EGID) and 1 more
Sites: Phoenix, Arizona; Apple Valley, California; La Jolla, California · 53 sites in all
- A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic EsophagitisPivotal-lookingActive, not recruiting
Uniquity One (UNI)Industry
NCT06598462 · 184 participants · Start Oct 16, 2024 · Primary completion Apr 30, 2027
Drug: Solrikitug Low Dose; Solrikitug Mid Dose and 1 more · For: Eosinophilic Esophagitis (EoE)
Sites: Dothan, Alabama; Glendale, Arizona; Peoria, Arizona · 73 sites in all
- A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of VSA006 in Chinese NASH PatientsActive, not recruiting
Visirna Therapeutics HK LimitedIndustry
NCT06322628 · 48 participants · Start Apr 22, 2024 · Primary completion Jul 2026
Drug: VSA006; Placebo · For: Nash
Sites: Beijing, China
- MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and HypertriglyceridemiaActive, not recruiting
MediciNovaIndustry
NCT05464784 · 40 participants (planned) · Start Aug 22, 2022 · Primary completion Dec 31, 2026
Drug: MN-001; MN-001 placebo · For: Diabetes Mellitus, Type 2; Hypertriglyceridemia; Non-Alcoholic Fatty Liver Disease
Sites: Las Vegas, Nevada; Edinburg, Texas
- Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS)Active, not recruiting
TRYP TherapeuticsIndustry
NCT06206265 · 14 participants · Start Jan 17, 2024 · Primary completion Mar 1, 2026
Drug: TRYP-0082 · For: Irritable Bowel Syndrome
Sites: Boston, Massachusetts
- Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic SteatohepatitisPivotal-lookingActive, not recruiting
Rivus Pharmaceuticals, Inc.Industry
NCT05979779 · 219 participants · Start Sep 5, 2023 · Primary completion Jan 21, 2025
Drug: HU6 · For: Non-Alcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis; Fatty Liver
Sites: Chula Vista, California; Los Angeles, California; Montclair, California · 20 sites in all
- A Randomized, Double-blind, Placebo-controlled Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)Pivotal-lookingActive, not recruiting
Guangdong Raynovent Biotech Co., LtdIndustry
NCT05692492 · 180 participants · Start Jun 3, 2023 · Primary completion Jun 16, 2026
Drug: ZSP1601; ZSP1601 and 1 more · For: Nonalcoholic Steatohepatitis (NASH)
Sites: Guangzhou, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.